116 related articles for article (PubMed ID: 1377687)
21. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
22. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
23. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
[TBL] [Abstract][Full Text] [Related]
24. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
[TBL] [Abstract][Full Text] [Related]
25. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.
Waltz DA; Chapman HA
J Biol Chem; 1994 May; 269(20):14746-50. PubMed ID: 7514182
[TBL] [Abstract][Full Text] [Related]
26. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
27. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
28. Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase.
Marchina E; Barlati S
Int J Biochem Cell Biol; 1996 Oct; 28(10):1141-50. PubMed ID: 8930138
[TBL] [Abstract][Full Text] [Related]
29. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Albo D; Rothman VL; Roberts DD; Tuszynski GP
Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
[TBL] [Abstract][Full Text] [Related]
30. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
31. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
32. Identification of the urokinase receptor as an adhesion receptor for vitronectin.
Wei Y; Waltz DA; Rao N; Drummond RJ; Rosenberg S; Chapman HA
J Biol Chem; 1994 Dec; 269(51):32380-8. PubMed ID: 7528215
[TBL] [Abstract][Full Text] [Related]
33. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.
Colman RW; Pixley RA; Najamunnisa S; Yan W; Wang J; Mazar A; McCrae KR
J Clin Invest; 1997 Sep; 100(6):1481-7. PubMed ID: 9294114
[TBL] [Abstract][Full Text] [Related]
34. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
35. Regulation of plasminogen receptor expression on monocytoid cells by beta1-integrin-dependent cellular adherence to extracellular matrix proteins.
Kim SO; Plow EF; Miles LA
J Biol Chem; 1996 Sep; 271(39):23761-7. PubMed ID: 8798602
[TBL] [Abstract][Full Text] [Related]
36. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
37. Effect of hypoxia on cellular adhesion to vitronectin and fibronectin.
Lash GE; Fitzpatrick TE; Graham CH
Biochem Biophys Res Commun; 2001 Sep; 287(3):622-9. PubMed ID: 11563840
[TBL] [Abstract][Full Text] [Related]
38. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
[TBL] [Abstract][Full Text] [Related]
39. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
Ellis V; Wun TC; Behrendt N; Rønne E; Danø K
J Biol Chem; 1990 Jun; 265(17):9904-8. PubMed ID: 2161846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]